Small Molecules

15 Nov 2019 Qtrilmet approved in the EU for the treatment of type-2 diabetes
15 Nov 2019 U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
15 Nov 2019 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
15 Nov 2019 FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options
14 Nov 2019 VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
14 Nov 2019 US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review
13 Nov 2019 Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program
13 Nov 2019 EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform
13 Nov 2019 Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
13 Nov 2019 Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
13 Nov 2019 Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial
13 Nov 2019 Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH
13 Nov 2019 DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting
13 Nov 2019 X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome
13 Nov 2019 Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
12 Nov 2019 Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease
12 Nov 2019 Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes
12 Nov 2019 Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
12 Nov 2019 Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
12 Nov 2019 Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
12 Nov 2019 Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019
12 Nov 2019 Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
12 Nov 2019 Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
12 Nov 2019 Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome
12 Nov 2019 Novartis data show tropifexor (LJN452) significantly improves several key biomarkers of NASH in patients with moderate to severe fibrosis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up